HouseH.R. 9774119th Congress
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
Full Text
Official text as published. Use Ctrl+F / Cmd+F to search within the document.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9774 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 9774
To amend the Federal Food, Drug, and Cosmetic Act to provide for
expedited approval of priority nonprescription drugs, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
July 20, 2026
Mr. Latta (for himself and Mr. Landsman) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to provide for
expedited approval of priority nonprescription drugs, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. PRIORITY NONPRESCRIPTION DRUGS.
(a) In General.--The Federal Food, Drug, and Cosmetic Act is
amended by inserting after section 506L (21 U.S.C. 356l) the following:
``SEC. 506M. PRIORITY NONPRESCRIPTION DRUGS.
``(a) In General.--
``(1) Designation.--The Secretary may, at the request of
the sponsor of a nonprescription drug, designate as a priority
nonprescription drug under this section a drug intended for
nonprescription use that is subject to an application submitted
(or to be submitted) under section 505(b), if the Secretary
determines that the drug meets the criteria specified in
subsection (d).
``(2) Nonprescription defined.--In this section, the term
`nonprescription' means, with respect to a drug, that such drug
is not subject to section 503(b)(1).
``(b) Request for Designation.--The sponsor of a drug subject to a
pending application under section 505(b) for nonprescription use may
request that the Secretary designate the drug as a priority
nonprescription drug.
``(c) Designation.--Not later than 60 calendar days after the
receipt of a request under subsection (b), the Secretary shall
determine whether a drug meets the criteria for designation as a
priority nonprescription drug under this section, and if so, make such
designation.
``(d) Criteria.--
``(1) Eligibility.--Except as provided in paragraph (2), a
drug described in subsection (a) is eligible for designation as
a priority nonprescription drug if--
``(A) the drug is intended for a novel
nonprescription indication that could provide a
meaningful public health benefit;
``(B) the drug is a new molecular entity; or
``(C) the drug contains an active ingredient that
has never been available in a nonprescription drug.
``(2) Exclusion.--A drug is not eligible for designation as
a priority nonprescription drug if the drug is subject to a
risk evaluation and mitigation strategy under section 505-1 or
if the drug is a controlled substance (as defined in section
102 of the Controlled Substances Act).
``(e) Actions.--If the Secretary designates a drug as a priority
nonprescription drug, the Secretary shall take such actions as are
appropriate to facilitate the development of, and expedite the review
of, an application or supplement to an application for such drug, which
may include--
``(1) holding meetings with the sponsor and the review team
throughout the development of the drug;
``(2) providing timely advice to, and interactive
communication with, the sponsor regarding the development of
the drug to ensure that the development program to gather the
nonclinical and clinical data necessary to demonstrate the
inapplicability of the criteria described in section 503(b)(1)
is as efficient as practicable;
``(3) involving senior managers and experienced review
staff, as appropriate, in a collaborative, cross-disciplinary
review;
``(4) assigning a cross-disciplinary project lead for the
Food and Drug Administration team to facilitate an efficient
review of the development program and to serve as a scientific
liaison between the review team and the sponsor; and
``(5) taking steps to ensure that the design of any
necessary nonclinical or clinical trials is as efficient as
practicable, when scientifically appropriate, including
reliance on real world evidence.
``(f) List of Conditions.--
``(1) Establishment.--Not later than 18 months after the
date of enactment of this section, the Secretary shall publish
in the Federal Register a list of conditions for which a
nonprescription drug, if developed for the condition, could
provide meaningful public health benefit.
``(2) Public comment.--The Secretary shall provide a period
of not less than 30 days for public comment on--
``(A) the list under paragraph (1); and
``(B) any updates to such list.''.
(b) Rule of Construction.--The amendment made by subsection (a)
shall not be construed to alter the evidentiary standards or the
information required for approval of a nonprescription drug under
section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355).
(c) Report to Congress.--Not later than 4 years after the date of
enactment of this Act, the Secretary of Health and Human Services shall
submit to Congress a report containing--
(1) the number of nonprescription drugs for which a sponsor
requested that the Secretary designate such a drug as a
priority nonprescription drug under section 506M of the Federal
Food, Drug, and Cosmetic Act, as added by subsection (a);
(2) the number of nonprescription drugs for which the
Secretary approved such request;
(3) the number of priority nonprescription drugs (as
designated under such section) for which the Secretary approved
an application under section 505 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355);
(4) an overview of the resources used to implement such
section; and
(5) any recommendation on further improvement on increasing
over-the-counter drug approvals using a framework similar to
the designation framework established in such section.
(d) Sunset Date.--The authority provided to the Secretary of Health
and Human Services under section 506M of the Federal Food, Drug, and
Cosmetic Act, as added by subsection (a), shall cease to be effective
September 30, 2032.
<all>